Product LaunchVertex launched Casgevy for treating both sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), indicating strong commercial execution.
Regulatory EndorsementVRTX gained regulatory endorsement to expand the Ph1/2 study of stem cell-derived, fully differentiated islet cell therapy VX-880 in Type 1 diabetes, advancing towards pivotal development.
Revenue GuidanceManagement increased 2024 revenue guidance to $10.65B-$10.85B, up 7.9%-9.9% y/y due to 2Q24 performance.